Artículos de revistas
Postoperative Complications In The Ahmed Baerveldt Comparison Study During Five Years Of Follow-up
Registro en:
American Journal Of Ophthalmology. Elsevier Science Inc, v. 163, p. 75 - 82, 2016.
0002-9394
1879-1891
WOS:000371447500012
10.1016/j.ajo.2015.11.023
Autor
Budenz
Donald L.; Feuer
William J.; Barton
Keith; Schiffman
Joyce; Costa
Vital P.; Godfrey
David G.; Buys
Yvonne M.
Institución
Resumen
To compare the late complications in the Ahmed Baerveldt Comparison Study during 5 years of follow-up. DESIGN: Multicenter, prospective randomized clinical trial. METHODS: SETTING: Sixteen international clinical centers. STUDY POPULATION: Two hundred seventy-six subjects aged 18.85 years with previous intraocular surgery or refractory glaucoma with intraocular pressure of > 18 mm Hg. INTERVENTIONS: Ahmed Glaucoma Valve FP7 or Baerveldt Glaucoma Implant BG 101-350. MAIN OUTCOME MEASURES: Late postoperative complications (beyond 3 months), reoperations for complications, and decreased vision from complications. RESULTS: Late complications developed in 56 subjects (46.8 +/- 4.8 5-year cumulative % SE) in the Ahmed Glaucoma Valve group and 67 (56.3 +/- 4.7 5-year cumulative % +/- SE) in the Baerveldt Glaucoma Implant group (P=.082). The cumulative rates of serious complications were 15.9% and 24.7% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups, respectively (P=.034), although this was largely driven by subjects who had tube occlusions in. the 2 groups (0.8% in the Ahmed Glaucoma Valve group and 5.7% in the Baerveldt Glaucoma Implant group, P=.037). Both groups had a relatively high incidence of persistent diplopia (12%) and corneal edema (20%), although half of the corneal edema cases were likely due to pre-existing causes other than the aqueous shunt. The incidence of tube erosion was 1% and 3% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups, respectively (P=.04). CONCLUSIONS: Long-term rates of vision-threatening complications and complications resulting in reoperation were higher in the Baerveldt Glaucoma Implant than in the Ahmed Glaucoma Valve group over 5 years of follow-up. (C) 2016 by Elsevier Inc. All rights reserved. 163 75 82 NIH [P30 EY014801] RESEARCH TO PREVENT BLINDness, New York, New York, USA (University of North Carolina) RESEARCH TO PREVENT BLINDness, New York, New York, USA (University of Miami) New World Medical, Inc Rancho Cucamonga, California, USA (University of Miami)